2008 Volume 26 Pages 35-38
Hepatocellular carcinoma (HCC) is an important clinical issue in Japan because of high prevalence and poor prognosis. HCC is treated by surgical operation including liver transplantation, microwave coagulo-necrotic therapy, radiofrequency ablation (RFA), percutaneous ethanol injection therapy (PEIT) and/or transcatheter arterial chemoembolization (TACE). Recent advance in these treatments can improve the prognosis of HCC. HCC is, however, multi-centrically occurred based on liver cirrhosis and chronic hepatitis. Therefore, physicians should treat not only HCC but also liver cirrhosis and hepatitis to patients with HCC.